Phaseline

Companies › Zhejiang Teruisi Pharmaceutical

Zhejiang Teruisi Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRS005
Anti-CD20 monoclonal antibody-MMAE antibody-drug conjugate
CD20, MMAEPhase 1CD20-positive B-cell Non-Hodgkin Lymphoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05395533TRS005Phase 1CD20-positive B-cell Non-Hodgkin LymphomaOncologyJul 2025

Targets

CD20 (1) MMAE (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Shanghai Jiaolian Drug Research and Development Lyell Immunopharma AvenCell Therapeutics Adicet Therapeutics Cellectis Biocad Gilead Sciences Shanghai AbelZeta

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.